MOXIFLOXACIN

Niksan Pharmaceutical is world’s leading manufacturer, trader, exporter and supplier of the Moxifloxacin HCL API and Moxifloxacin HCL formulations. Niksan Pharmaceutical manufactures large quantity of Moxifloxacin HCL API and finished products in Ankleshwar, Gujarat, India. Niksan Pharmaceutical and Niksan group companies are the largest manufacturers and suppliers of Moxifloxacin HCL products.

Niksan Pharmaceutical exporting very big quantity of the fine quality products of Moxifloxacin HCL in all over world for many years  in a countries like Canada, USA, Romania, Finland, Malaysia, Netherland, South Africa, Brazil, Egypt, Singapore, Jordan, Lebanon, Israel, Vietnam, Bangladesh, Paraguay, Argentina, Dominican Republic, Sudan, 'Hong Kong, S.A.R., China', Seychelles, Algeria, Iran, Uruguay, Russia, Thailand, Afghanistan, Latvia, Lithuania, United Arab Emirates, Seychelles, Peru, Switzerland, Tunisia, France, Hungary, Finland, Turkey, Pakistan, Rwanda, South Africa, Denmark, Malawi, Croatia, Slovenia, Ireland, Zambia, Cyprus, Nigeria, Uzbekistan, Cameroon, Netherlands, Azerbaijan, Venezuela, Morocco, Cote D Ivoire, St Lucia, South Korea, Congo, Philippines, Colombia Sweden, Hungary, Mauritius, Vanuatu, Malta, Kazakistan, Slovenia, Bolivia, Japan, Uganda, Australia and many more countries.

Niksan Pharmaceutical also supplies large quantity of Moxifloxacin HCL products in Indian states like Gujarat, Haryana, Rajasthan, Madhya Pradesh, Kerala, Tamilnadu, Delhi, Bihar, Uttar Pradesh, Assam, Goa, Hyderabad, Telangana, Mizoram, Sikkim etc.

Moxifloxacin HCL is one type of antibiotic. Moxifloxacin HCL belongs to the class called fluoroquinolone. Moxifloxacin HCL gives antibiotic activity by killing the bacteria. Moxifloxacin HCL used in the treatment of pneumonia, tuberculosis, conjunctivitis.

Moxifloxacin HCL available in tablet, creams, ointments and capsules.

SYNONYMS: Moxifloxacin HCL, Moxifloxacino HCL

IUPAC NAME: 1-Cyclopropyl-6-fluoro-8-methoxy-7-[(4aS,7aS)-octahydro-6H-pyrrolo[3,4-b]pyridin-6-yl]-4-oxo-1,4-dihydro-3-quinolinecarboxylic acid hydrochloride

CAS NO: 12-8039

MOLECULAR FORMULA: C21H25ClFN3O4

MOLECULAT MASS: 437.89 g·mol−1

STORAGE CONDITIONS: Store in cool and dry place, away from direct sun light and heat. Do not store medicine in bathroom or any humid place. Keep away from children and pets.

HOW TO USE: Take medicine orally with or without food once per day. Wash eyes and remove the lance before using Moxifloxacin ophthalmic solution. Do not consume the ophthalmic solution. Take your doctor’s advice if you have any confusion related to the medicine.

HOW MOXIFLOXACIN HCL WORKS: Moxifloxacin inhibits the topoisomerase II and topoisomerase IV enzyme. By inhibiting these enzymes Moxifloxacin inhibits the replication of DNA. And also inhibits the cell division of the bacteria.

PHARMACOKINETICS: Moxifloxacin absorbed rapidly after oral administration having bioavaibility of 90%. Almost 50% of drug binds with plasma proteins. Half life of Moxifloxacin is between 11.5-15.6 hours. Approximately 45% of Moxifloxacin drug eliminated through urination and feces.

SIDE EFFECTS OF MOXIFLOXACIN: The commons side effects of Moxifloxacin are nausea, vomiting, headache, insomnia, weakness, dizziness are seen in patients. If you see signs of kidney problem, liver problem, GI problem like bleeding, stomach pain, abdominal discomfort, dark urine seek immediate medical attention. Moxifloxacin also cause some intestinal problem like bloody stool, abdominal pain, diarrhoea, cramping in intestine.

PRECAUTION: Tell your doctor if you have allergic reaction to Moxifloxacin medicine. If you have problem like liver problem, heart problem, depression, brain problem like Alzheimer’s, blood vessels problem, mood disorders, brain tumours, or any blood pressure problem tell your doctor before taking the medication. Moxifloxacin can increase the heart problems so kindly avoid the medicine if you have any heart related problems.

CDSCO APPROVAL: Moxifloxacin (0.5%) + Dexamethasone Phosphate (0.1%) Eye drops approved by CDSCO in India in 24.11.2005,

Moxifloxacin HCL (0.5%) + Ketorolac Tromethamine 0.5% Ophthalmic Solution approved by CDSCO in India in 11.07.2007,

Moxifloxacin tab. approved by CDSCO in India in 27.12.2001,

Difluprednate 0.05% w/v + Moxifloxacin 0.5% w/v Eye Drops approved by CDSCO in India in 22.09.2011

Moxifloxacin intravenous infusion approved by CDSCO in India in 13.02.2002

Moxifloxacin HCl (5mg) + Prednisolone Acetate (10mg) per ml. (eye drops) approved by CDSCO in India in 16.10.2007      

Ketorolac Tromethamine 0.4% w/v + Moxifloxacin 0.5% w/v ophthalmic solution approved by CDSCO in India in 21.09.2010

Loteprednol etabonate 0.5% w/v + Moxifloxacin 0.5% w/v ophthalmic Suspension approved by CDSCO in India in 01.12.2009

Moxifloxacin ophthalmic solution approved by CDSCO in India in 19.10.2007

Moxifloxacin eye ointment approved by CDSCO in India in 01.10.2008

Moxifloxacin HCl approved by CDSCO in India in 06.06.2001

Moxifloxacin HCl BP 0.5% w/v + Bromfenac Sodium 0.09% w/v Eye drop approved by CDSCO in India in 05.01.2011

Moxifloxacin ophthalmic solution 0.5% approved by CDSCO in India in 27.08.2004

Moxifloxacin Eye Ointment (5mg/gm) approved by CDSCO in India in 06.02.2006

Cefixime (SR) 400mg + Moxifloxacin (SR) 400 mg Tablets approved by CDSCO in India in 08.08.2011

FORMULATIONS AVAILABLE IN MARKET:

Moxifloxacin (0.5%) + Dexamethasone Phosphate (0.1%) Eye drops

Moxifloxacin HCL (0.5%) + Ketorolac Tromethamine 0.5% Ophthalmic Solution

Moxifloxacin tablets

Difluprednate 0.05% w/v + Moxifloxacin 0.5% w/v Eye Drops

Moxifloxacin intravenous infusion

Moxifloxacin HCl (5mg) + Prednisolone Acetate (10mg) per ml. (eye drops)

Ketorolac Tromethamine 0.4% w/v + Moxifloxacin 0.5% w/v ophthalmic solution

Loteprednol etabonate 0.5% w/v + Moxifloxacin 0.5% w/v ophthalmic Suspension

Moxifloxacin HCl BP 0.5% w/v + Bromfenac Sodium 0.09% w/v Eye drop

Moxifloxacin Eye Ointment (5mg/gm)

Cefixime (SR) 400mg + Moxifloxacin (SR) 400 mg Tablets

Note: Product protected by valid patents are not offered for sale in countries where such patents are still valid and its liability is at Buyers Risk.

REFERENCES:

www.webmd.com

https://pubchem.ncbi.nlm.nih.gov

https://go.drugbank.com

https://cdscoonline.gov.in

https://www.wikipedia.org/

https://www.drugs.com

https://www.zaubacorp.com

https://www.practo.com/consult